Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex Pharmaceuticals

450.50
+6.681.51%
Post-market: 450.500.00000.00%18:58 EDT
Volume:960.50K
Turnover:431.61M
Market Cap:115.69B
PE:-117.27
High:451.66
Open:443.83
Low:443.83
Close:443.82
Loading ...

TRADING DAY-Absent tariff clarity, nerves fray

Reuters
·
07 May

Drug Stocks Hit By D.C. Developments -- Market Talk

Dow Jones
·
07 May

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-05-06

Reuters
·
07 May

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

Dow Jones
·
07 May

Why Vertex Pharmaceuticals Stock Is Sinking Today

Motley Fool
·
06 May

Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
06 May

Stock Track | Vertex Pharmaceuticals Plummets 6.92% on Q1 Earnings Miss and Downgrade

Stock Track
·
06 May

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $621 From $617

MT Newswires Live
·
06 May

Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald

Dow Jones
·
06 May

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Marriott, IQVIA

Reuters
·
06 May

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Eaton, Lemonade

Reuters
·
06 May

Stock Track | Vertex Pharmaceuticals Plunges 5.04% Pre-market on Q1 Revenue Miss and Downgrade

Stock Track
·
06 May

BUZZ-Vertex Pharma falls after Q1 results miss

Reuters
·
06 May

Vertex Pharmaceuticals Inc : Scotiabank Cuts Target Price to $442 From $450

THOMSON REUTERS
·
06 May

Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
06 May

Leerink Partners Downgrades Vertex Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $503 From $550

MT Newswires Live
·
06 May

Vertex Pharmaceuticals: Hold Rating Amid Revenue Misses and Strategic Outlook

TIPRANKS
·
06 May

Vertex Pharmaceuticals downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
06 May

Vertex Pharmaceuticals: Strong Market Performance and Promising Future Prospects Reinforce Buy Rating

TIPRANKS
·
06 May

Vertex Pharmaceuticals Inc (VRTX) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Challenges

GuruFocus
·
06 May